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Enterovirus  71  (EV71)  is  a common  pathogen  for hand,  foot,  and mouth  disease  (HFMD),  which  has
signiﬁcant  morbidity  and  mortality,  and  for which  children  aged  6–59  months  age  are  at  highest  risk.
Due  to lack of effective  treatment  options,  control  of  EV71  epidemics  has  mainly  focused  on  development
of  EV71  vaccines.  Clinical  trials  have  been  completed  on  3 EV71  vaccines,  with  trial  results  demonstrating
good  vaccine  efﬁcacy  and  safety.  When  EV71  vaccine  is approved  by  China’s  national  regulatory  authority,
an  evidence-based  strategy  should  be developed  to optimize  impact  and  safety.  An  immunization  strategy
for EV71  vaccine  should  consider  several  factors,  including  the  target  population  age  group,  the  numberand, foot, and mouth disease
accine
mmunization strategy
of  doses  for  primary  immunization,  the  need  for  a booster  dose,  concomitant  administration  of  other
vaccines,  economic  value,  program  capacity  and logistics,  and  public  acceptance.  Once  EV71  vaccines  are
in  use,  vaccine  effectiveness  and  safety  must  be  monitored  in  large  populations,  and the  epidemiology  of
HFMD  must  be evaluated  to  assure  a match  between  vaccination  strategy  and  epidemiology.  Evaluation
in China  is  especially  important  because  there  are no other  EV71  vaccines  globally.. Introduction
Hand, foot, and mouth disease (HFMD) is a common enterovi-
al infection, most frequently caused by coxsackievirus A16 (CV
16) and enterovirus 71 (EV71) [1,2]. Most patients show mild
nd self-limiting illness, but some patients rapidly develop central
ervous system (CNS) complications that can be fatal—especially
FMD caused by EV71 virus. Young children <3 years old are the
ost susceptible to EV71 infection and have the highest risk CNS
nvolvement, which is why the pathogen has captured much atten-
ion [3–5].
The relatively high incidence of disease caused by EV71 is rec-
gnized as a serious public health problem. Due to lack of effective
reatment options, control of EV71 epidemics has mainly focused
n development of EV71 vaccines. Three manufactures in mainland
hina have recently completed phase III trials for EV71 vaccines and
ave applied for licensure approval from the China Food and Drug
dministration (CFDA).
As human EV71 vaccines move closer to the China market, it
s necessary for policy makers, public health ofﬁcials, clinicians,
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and other government vaccination program decision makers to
consider how to use such a vaccine. Introduction of EV71 vaccine
will have unique challenges. EV71 vaccine, if licensed and rec-
ommended, will be the ﬁrst vaccine introduced in China without
experience in other countries. Thus, developing a robust, evidence-
based immunization policy may  be difﬁcult. Introduction of this
vaccine may  change EV71 disease epidemiology, and so potential
risks related to a changing epidemiology must be considered prior
to introduction. In this article we  discuss considerations for the
development of an immunization strategy for this vaccine.
2. Methods
A working group from the national immunization program (NIP)
of the Chinese Center for Disease Control and Prevention (CCDC)
and the Center for Drug Evaluation (CDE) of the China Food and
Drug Administration (CFDA), reviewed information relevant to the
development of an EV71 immunization strategy. We  reviewed liter-
ature published before March of 2014 on the epidemiology of HFMD
and EV71 infection in mainland China, clinical data (including efﬁ-
cacy, safety, immunogenicity, and immune persistence) of EV71
vaccines in Chinese children, the economic value of EV71 vaccines,
potential immunization schedules for EV71 vaccines, public accep-
tance and willingness-to-pay for an EV71 vaccine, and challenges
of EV71 vaccine policy.
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. Epidemiology and disease burden
.1. Epidemiology and seroepidemiology of EV71 and HFMD
The ﬁrst EV71 case was reported in the United States in 1969.
ince 1998, there has been a continually increasing trend of EV71
nfection-related epidemics in the Western Paciﬁc Region of the
orld Health Organization, including in mainland China [5–9],
alaysia [10,11], Vietnam [12], Singapore [13,14], Thailand [15],
ong Kong (China) [16], and Taiwan (China) [17,18]. In Taiwan
China), after the largest EV71 epidemic, which happened in 1998
nd caused 405 serious neurological complications and 78 deaths,
V71 caused additional epidemics: in 2000–2001, 2004–2005, and
008–2009 [18,19]. The country of Malaysia experienced 5 out-
reaks HFMD caused by EV71 since its ﬁrst recorded emergence
here in 1997 [10,11]. In Vietnam, EV71 was ﬁrst isolated in 2003,
nd an outbreak of HFMD caused by EV71 was reported in 2005.
etween February 2011 and July 2012, Vietnam reported a total
f 174,677 cases and 200 deaths [12]. In Singapore, recent EV71-
ssociated HFMD epidemics (140,000 cases and 8 deaths) occurred
n 2006 and 2008, with the 2008 outbreak being the largest known
FMD outbreak [13,14]. Thailand ﬁrst reported a large-scale HFMD
utbreak caused by EV71 in 2012 that included 39,000 cases and led
o 3 deaths [15]. Due to its signiﬁcant public health and social impli-
ations, EV71 infection has been a statutorily-notiﬁable disease in
ong Kong since March 2009 [20].
In mainland China, signiﬁcant increases in HFMD morbidity and
ortality have caused an enormous burden on the public health
ystem. Nationwide epidemics of HFMD started in 2008, beginning
ith an outbreak in Anhui province that spread rapidly to other
rovinces. In total, 488,955 young children suffered in this epidemic
hat had 1165 severe cases and 126 fatal cases [7]. In response to
hese large outbreaks, HFMD was listed as a category C notiﬁable
isease in China in May  2008.
A recent study characterized the epidemiology of HFMD in
hina on the basis of epidemiological, clinical, and laboratory data
hat were reported to the National Enhanced Surveillance System
etween 2008 and 2012 [5]. From 2008 to 2012, more than 7.2
illion cases of HFMD were reported, with an estimated incidence
f 1.2 per 1000 person-years from 2010 to 2012. HFMD has been
esponsible for 500–900 deaths each year, primarily among young
hildren. Young children less than 5 years old had the highest risk of
isease, with the highest incidence and mortality rate among chil-
ren aged 12 to 23 months (38.2 cases per 1000 and 1.5 deaths per
00,000 in 2012), followed by 6–11 months of age (28.9 cases per
000 and 1.3 deaths per 100,000 in 2012) and 24–59 months of age
23.1 cases per 1000 and 0.4 deaths per 100,000 in 2012). The inci-
ence has been low among infants younger than 6 months, older
hildren (age 5–14 years) and adults (age ≥ 15 years). The median
ge of reported cases was 27 months (IQR 18–43 months). Median
uration from onset to diagnosis was 1.5 days (IQR 0.5–2.5 days)
nd median duration from onset to death was 3.5 days (2.5–4.5
ays).
Each year in June, HFMD peaked in north China, whereas
outhern China had semiannual outbreaks in May  and during
eptember–October. Geographical differences in seasonal patterns
ere weakly associated with climate and demographic factors,
hich explained 8–23% and 3–19% of the variance, respectively.
s in other countries, EV71 predominated in laboratory-conﬁrmed
FMD cases, accounting for 45% of mild, 80% of severe, and 93%
f fatal cases. The case-severity rate of patients with cardiopul-
onary or neurological complications was 1.1% (range across years
.2–1.6%), the case-fatality rate was 0.03% (0.03–0.05%), and the
evere case-fatality rate was 3.0% (2.6–10.4%). A predominance
f EV71 serotypes was recorded in severe and fatal cases, with a
edian age of infection at 2.3 years. Consistently across all age015) 1107–1112
groups, EV71 infections were much more severe than were CV
A16 infections. Beyond young age and infection with EV71, several
risk factors, including rural residence and long onset-to-diagnosis
interval, were identiﬁed as predictors for mortality.
Previous studies suggested that infants older than 6 months of
age would be susceptible to EV71 infection due to waning maternal
antibody. A seroepidemiological study in Jiangsu province, China,
showed that infants aged 7 to 12 months had the lowest seroposi-
tivity against EV71, and the incidence of HFMD remained low until
14 months [21].
3.2. Estimating transmission dynamics of EV71
Vaccination coverage levels required to interrupt transmission
can be estimated from strain-speciﬁc basic reproductive num-
ber (R0) values. Approximate coverage values for each cohort, P,
required to stop transmission may  be derived from the relationship,
P > 1 − 1 R–0. However, few studies have evaluated transmission
dynamics of EV71 outbreaks. Ma  et al. reported that the median
R0 for EV71 in Taiwan was  5.48, which is considered moderately
infectious compared with other contagious diseases. Given this
value, 82% of a birth cohort would have to be immunized through
vaccination to stop sustained EV71 transmission in the cohort [22].
3.3. Economic and disease burden of EV71-associated HFMD
EV71-associated HFMD poses a substantial health and economic
burden in China. Quantifying this burden is critical to set policy
priorities and disease-control strategies.
As described above, millions of cases and thousands of deaths
due to HFMD have been reported annually in China since 2008, and
EV71 predominates in laboratory—conﬁrmed cases [5]. However,
the ofﬁcially reported cases are considered to reﬂect only a small
proportion of the cases. Medical care may  not be sought for clini-
cally mild cases. Many clinicians, especially in rural areas, lack the
necessary experience and knowledge required for the identiﬁcation
and diagnosis of severe and fatal cases, in which extremity rashes or
oral ulcers appear less frequently. In addition, township-, village-
and community- level health facilities are unable to carry out eti-
ological diagnosis, such as serotyping and genetic sequencing, due
to lack of laboratory capacity.
Although speciﬁc studies of the economic burden of EV71-
associated HFMD are not yet available, costs could be estimated
using data from cost-burden studies of HFMD [23]. We obtained an
average direct and indirect cost of US $129 (≈800 RMB) for an out-
patient, $484 (≈3000 RMB) for an inpatient, and $1936 (≈12,000
RMB) for a severe inpatient, respectively. If the proportion of EV71
infections for severe HFMD cases is assumed to be 80%, the annual
cost of severe EV71-associated HFMD would be about $29 mil-
lion (≈180 million RMB) (estimated by 90 thousand cases within
6 years). Because the distribution of outpatients and inpatients is
not available, by using varying estimated proportions, the annual
economic burden of mild EV71-associated HFMD would be about
$161–323 million (≈1000–2000 million RMB). The estimated cost
burden of EV71-associated HFDM would have been higher had we
considered other costs, such as fatal cases, long-term sequelae, and
cases managed outside of the healthcare system.
4. Vaccine candidates
The substantial and increasing morbidity and mortality of EV71-
associated HFMD have motivated development of EV71 vaccines.
Thus far, ﬁve organizations have completed pre-clinical devel-
opment of inactivated EV71 whole-virus vaccines and are in
different stages of clinical trials. Among these organizations, three
are in mainland China [Beijing Vigoo Biological Co., Ltd. (Vigoo)
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Table  1
Summary of EV71 vaccine candidates from mainland China.
Items Beijing Vigoo Sinovac CAMS
Manufacturing
processes
Cell lines Vero cell Vero cell Human diploid cell KMB-17
EV71  strain EV71 C4 subgenotype (strain
FY7VP5/AH/CHN/2008)
EV71 C4 subgenotype (strain
H07)
EV71 C4 subgenotype
(FY23strain)
Production technique Fermenter,
inactivation(serum-containing
media)
Cell factory, inactivation
(serum-containing media)
Roller bottle,
(serum-containing media)
Phase  3 efﬁcacy
trial
Trial design A multi-center, randomized,
double-blind,
placebo-controlled trial to
evaluate the efﬁcacy of the
EV71 vaccine against
EV71-associated disease,
including HFMD/HA, CNS
complications, and other
non-HFMD diseases caused by
EV71
A multi-center, randomized,
double-blind,
placebo-controlled trial to
evaluate the efﬁcacy of the
EV71 vaccine against
EV71-associated disease,
including HFMD/HA, CNS
complications, and other
non-HFMD diseases caused by
EV71
A multi-center, randomized,
double-blind,
placebo-controlled trial to
evaluate the efﬁcacy of the
EV71 vaccine against
EV71-associated HFMD/HA,
CNS complications
Period From January 2012 to March
2013, including 12-month
surveillance period
From January 2012 to March
2013, including 12-month
surveillance period
From March 2012 to February
2013, including 9-month
surveillance period
Target population Infants aged 6–35 months Infants aged 6–35 months Infants aged 6–71 months
Sample size 10,245 (5120 in vaccine group
and 5125 in placebo group)
10,077 (5044 in vaccine group
and 5033 in placebo group)
12,000 (6000 in vaccine group
and 6000 in placebo group)
Dosage (g of EV71) 320 U/0.5 ml  (0.5 g of EV71) 400 U/0.5 ml  (1.0 g of EV71) 100 U/0.5 ml
Clinical trials. Gov.
identiﬁer
NCT0150824 NCT0150785 NCT0156958
Regimen Two  dose with 28 days apart Two dose with 28 days apart Two dose with 28 days apart
Other  objectives Safety
Immunogenicity
Antibody persistence
Serological surrogate
Batches consistency
Safety
Immunogenicity
Antibody persistence
Serological surrogate
Safety
Immunogenicity
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yVaccine efﬁcacy (95%
CI) against EV71
associated HFMD
90.9% (70.4–97.2) 
19,24–26], Sinovac Biotech Ltd. (Sinovac) [27–30], and Institute
f Medical Biology, Chinese Academy of Medical Science (CAMS)
31,32] and have recently completed phase I to III trials for the
accines they developed. The other two vaccines, developed by
ational Health Research Institutes (NHRI) of Taiwan (China) [33]
nd Inviragen Pte., Ltd. (Inviragen), of Singapore, have been studied
n phase I clinical trials (Table 1).
For inactivated EV71 vaccines in mainland China, Vigoo, Sinovac
nd CAMS have established their respective C4 genotype vaccine
trains, using the seed lot system and cell banks of Vero (Vigoo
nd Sinovac) or diploid cells (CAMS) in accordance with WHO
uidelines and the Chinese Pharmacopoeia and related technical
uidance from CFDA. Recently published phase III reports showed
hat the EV71 vaccines developed by three manufactures in main-
and China all have good safety proﬁles in children less than 6
ears old and provide protective immunity against EV71 infection-
elated HFMD, with vaccine efﬁcacy of 90.9% for Vigoo [26], 94.6%
or Sinovac [30], and 97.4% for CAMS [32]. Although EV71 vaccines
ffered no protection against HFMD caused by CV A16 or other
nterovirus serotypes, other research suggested that EV71 vaccines
nduce broad cross-neutralizing activity against EV71 subgeno-
ypes B4, B5, C2, and C5, which were prominent epidemic strains in
ther Western-paciﬁc countries or areas [34]. These EV71 vaccine
andidates have entered into the vaccine evaluation and licensing
rocess of CFDA.
. Considerations for developing recommendations for
mmunization.1. Target population
Because the 3 manufactures recruited children 6 months to 3
ears old or 6 months to 5 years old in their phase III clinical trials94.8% (87.2–97.9) 97.4% (92.9–99.0)
for EV71 vaccine, the potential target age should be within these
age ranges. Decision makers should also consider the level of EV71
maternal antibodies in newborn infants when evaluating the age
distribution of disease. The immunization schedule should start at
the youngest age the vaccine is effective, and before the EV71 dis-
ease incidence increases. According to available data, the lowest
level of maternal antibody to EV71 during infancy is 7–12 months
of age, and the peak disease incidence occurs at 12–23 months of
age. Therefore, vaccination starting at 6 months age could protect
children in a timely manner, before maternal antibodies disappear.
Since the incidence rates of disease among children over 5 years
old and among adults are very low, EV71 vaccine use over the age
of 5 years will have limited beneﬁt at either the individual level
or the population level, with correspondingly little public health
signiﬁcance and cost-effectiveness.
In summary, the EV71 vaccine should be considered for children
from 6 month to 59 months or age, as early as possible, completing
the schedule before 12 months of age. For children over 5 years of
age, we  would not recommend using EV71 vaccine unless the epi-
demiology changes such that older children begin acquire disease
at substantially higher rates.
5.2. Immunization schedule
Based on the results from EV71 vaccine clinical trials, the
immunogenicity of a single dose of vaccine does not provide protec-
tive immunity; however 2 doses, separated by at least one month,
are protective.
There is no evidence to support use of a booster dose for EV71
vaccine at this time. We  should closely monitor the persistence of
EV71 antibody levels, long-term protection with the vaccine, and
vaccine effectiveness following the vaccine’s introduction. Several
years of vaccinating young children with only a primary series will
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esult in lower exposure to EV71 virus. In this situation, waning
mmunity following vaccination could lead to the need for a booster
ose.
The China immunization schedule is crowded during the ﬁrst
 years of life. If EV71 vaccine is to be started at 6 months of
ge, its administration will overlap with administration of hepati-
is B vaccine at 6 months; measles containing vaccine (MCV) and
apanese encephalitis vaccine (JE) at 8 months; group A meningo-
occal polysaccharide vaccine from 6 to 18 months; hepatitis A
accine at 18 months; and MMR,  diphtheria–tetanus–acellular-
ertussis, and JE vaccines at 18–24 months.
In order to improve vaccine uptake and reduce missed opportu-
ities to vaccinate, we usually encourage co-administration of two
r more age-recommended vaccines at a single clinic visit.
As an inactivated vaccine, EV71 vaccine should not have
roblems with immunogenicity or safety when administered con-
urrently with other vaccines. However, there are no data on
oncurrent vaccination with EV71 vaccine. Before such data are
vailable, we could consider the ﬁrst dose of EV71 to be given at
 months of age followed by a second dose at 9 months. Neither
ge is currently used for vaccination in the China immunization
chedule. Meanwhile, co-administration of EV71 with other vac-
ines should be studied. When the appropriate data are available,
e could consider two doses of EV71 vaccine given concurrently
ith other vaccines starting at 6 months of age.
.3. Forecasting the economic value of EV71 vaccines
Understanding a vaccine’s potential economic value prior to
icensure can identify appropriate target populations, establish
accine price points, and ultimately improve acceptance for a vac-
ine. As per WHO  convention, a cost-effectiveness threshold based
n China’s gross domestic product (GDP) per capita can be used
o determine economic value. Vaccination is considered highly
ost-effective when the incremental cost-effectiveness ratio (ICER)
s less than the GDP per capita, cost-effective when the ICER is
etween one and three times the GDP per capita, and not cost-
ffective when the ICER exceeds three times the GDP per capita.
A study conducted in 2010 suggested that routine vaccination
f EV71 vaccine in China (estimated EV71 infection incidence of
.04%) may  be cost-effective when the vaccine costs $25 or less
nd vaccine efﬁcacy is ≥70%, or vaccine cost is $10 and efﬁcacy
50% [35]. Since additional evidence of vaccine safety, efﬁcacy,
nd other information (e.g., dose requirements) are now available
rom the phase I to III clinical trials, we can better understand the
ost-effectiveness of EV71 vaccine. In the phase III trials of the
hree EV71 vaccine candidates, the EV71 infection incidence in the
lacebo group ranged from 6.7 to 25.2 cases per 1000 person-year
mong young children less than 6 years of age, and the efﬁcacy of
he vaccines against HFMD caused by EV71 was 90.9–97.4% in the
ntention-to-treat population. Using this information in the model
bove, even at the lowest EV71 risk in China (0.6%), immunization
s highly cost-effective when vaccination costs are ≤$75 with 90%
accine efﬁcacy.
.4. Vaccine usage
There are two options of using a new vaccine like EV71 vaccine
n China—in the private market or in the national immunization
rogram. In recent years, new vaccines have been introduced ﬁrst
nto the private market of both developed and developing coun-
ries, and this subsequently paved the way for introduction into the
ublic sector. However, if EV71 vaccine is used in the private mar-
et only, it will be difﬁcult to achieve high coverage, especially if the
accine is expensive and must be paid for out-of-pocket by parents.
hus, children who receive the vaccine could be protected, but the015) 1107–1112
population may  not have sufﬁcient herd immunity, which is around
82%, to interrupt transmission in communities due to low coverage.
There are several factors which could impact EV71 vaccine
introduction into a government’s national immunization program.
These include burden of EV71-associated HFMD, perception of dis-
ease importance, ability of the country to ﬁnance vaccine purchase
with or without donor support, evidence of safety and effective-
ness for the new vaccine from large population usage, capacity of
the immunization system, and political and other considerations.
If we have enough information from phase VI clinical trials and
post marketing surveillance and decide to introduce the vaccine
into the national immunization program, we also need to consider
whether a catch-up program is necessary. Such a decision could
be based on surveillance data, policy history, vaccine uptake, and
serological survey studies. A catch up campaign could build herd
immunity quickly and then be followed by routine immunization
with high coverage for new birth cohorts. Such a strategy might
eliminate EV71 transmission, if this is a goal of control for EV71
related HFMD. A modeling study will be helpful to additional clarity
on which immunization strategy is most acceptable for China.
In addition to private use, routine immunization, and catch up
immunization policies, we  might also consider other immuniza-
tion activities. First, we  might consider partial introduction into
the immunization program if introduction into the entire country
is not possible or not necessary. Such a policy will need criteria for
selecting areas based on the epidemiology and laboratory surveil-
lance of EV71 disease. Second, we  might need to consider whether
EV71 vaccine can be used during an outbreak. The effectiveness
of outbreak response immunization would need to be carefully
evaluated.
5.5. Public acceptance and willingness-to-pay for an EV71
vaccine
Public acceptance should be considered in light of a novel
vaccine without any experience by the public. Evidence shows con-
cerns over the safety of vaccines, big business involvement, and
the introduction of a vaccine into the EPI system. Public concerns
can affect parental decisions to vaccinate. Parents should know
that the current developed EV71 vaccines have been viewed as
a promising solution for controlling severe or fatal HFMD, which
is overwhelmingly caused by EV71, but might offer no protection
against HFMD/HA caused by CV A16 or other enterovirus serotypes.
The studies on vaccine acceptance for EV71 vaccine need to be
done to explore public acceptance and willingness-to-pay (WTP)
for EV71, as well as the price range of WTP  if the vaccine will be
used in private market.
6. Considerations for post marketing monitoring
The usage of a vaccine might change the disease epidemiology,
and related risks should be considered before vaccine introduc-
tion. Once the vaccine is introduced, post-marketing monitoring
for safety, impact, and epidemiological changes is essential.
6.1. Post marketing evaluation
The results of clinic trials show that vaccine efﬁcacy and safety
are good for all three potential vaccines; however, the three vac-
cines were made using different virus strains and dosages, and
the clinical trials were conducted in different sites. Since sample
sizes are limited during prelicensure clinical trials, rare adverse
reactions may  go undetected. Therefore, as a new vaccine with no
global experience, the safety proﬁle that emerges when EV71 vac-
cine is used in a large population must be monitored carefully. A
consolidated phase IV clinical trial that includes all three vaccines
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ight be helpful to assess efﬁcacy and optimize dosage. In addition,
o-administration with other vaccines, emergency immunization
esponse effectiveness, and persistency of protection should be part
f EV71 post marketing evaluation.
.2. Potential change of the epidemiological characteristics of
FMD
Widespread use of EV71 vaccine will impact natural trans-
ission of wild EV71 virus and might change its epidemiological
haracteristics. Use of the vaccine could cause short-term effects
nd long-term effects. Short-term effects include that the vaccine
an provide protection to the individual after vaccination, and, if the
overage is high, the incidence of the disease could decrease rapidly
ollowing vaccine introduction. The long-term effect of vaccination
ill be a slower process—we may  need to monitor epidemiological
hanges for several years or even decades. One of the long-term
isks is that when vaccine is used in private market and the cover-
ge is neither very high nor very low, the incidence of the disease
ould decrease compared with pre-vaccine era, but many individu-
ls would remain unprotected. This will lead to a situation in which
nvaccinated children have a small chance to be infected by wild
V71 infection, and they could remain susceptible to older ages,
ven to adulthood. When susceptibility shifts from young children
o older children and adults, the epidemiologic characteristics could
lso change, as the peak age group may  occur in older children and
dults. If this risk is identiﬁed through the surveillance system, we
ight consider introducing EV71 vaccine into the routine immu-
ization program after a wide catch up campaign to reduce the size
f the susceptible population.
The use of EV 71 vaccine could build herd immunity in the pop-
lation and could produce selective pressures on EV71 and related
iruses circulating in the environment. The pathogen spectrum of
FMD may  change to CV A16 or other viruses that could cause
erious disease. In order to monitor this possibility, we  need to
trengthen the laboratory-based surveillance system.
.3. Future vaccine research and development
A logical next step of vaccine development for HFMD is multiva-
ent vaccines and combination vaccines. Multivalent vaccines could
e developed with EV71 and CV A16 virus antigens to provide more
omprehensive protection for HFMD. However, decisions should
e based on analysis of CV A16 pathogenesis, disease burden, the
everity of the disease, cost analysis, and other considerations
efore deciding whether it is necessary to invest in CV A16 vaccine
evelopment.
For combination vaccines, we can learn lessons from IPV-
ontaining combination vaccine development. Combination vac-
ines against a variety of diseases will greatly improve accessibility
f the routine immunization program. The potential antigens that
ould be considered in combination with EV71 vaccine include IPV,
TP, HBV, Hib, and possibly others. However, most of them are
dministered to children before 6 months of age, and so addition
tudy of the EV71 vaccine of infants younger than 6 month will be
eeded.
. Conclusions
EV71 vaccine will be available soon. Immunization strategy
hould be based on disease epidemiology, vaccine characters, eco-
omic analysis, potential for changes in disease epidemiology, and
rogram demand. Once EV71 is introduced, monitoring for safety,
accine effectiveness, and impact are essential in order to update
accination strategy with emerging evidence.
[015) 1107–1112 1111
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